drugset / Trial / NCT05159830

Cannabidiol for Reducing Drinking in Alcohol Use Disorder

NCT05159830 ↗

Phase 2 Terminated 10 enrolled Hôpital le Vinatier
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The non-psychotomimetic cannabis compound cannabidiol (CBD) has been found effective for reducing alcohol drinking in mice. Moreover, other experimental studies have found that CBD reduced alcohol-induced steatosis in the liver, and reduced alcohol-related injury in the brain. Despite these promising results from animal data, no human study has been conducted yet in alcohol use disorder (AUD).

Timeline

Start
2024-10-25
Primary completion
2026-02-26
Completion
2026-02-26

Outcome

Outcome not reported

Stopped: “Péremption des unités de traitement prévue début juin 2026. Compte tenu des délais de traitement, aucune administration ne sera plus possible après le 1 février 2026. Ces facteurs ne permettent plus de garantir la poursuite des inclusions.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified 600 mg Oral